SHL Telemedicine Ltd (SHL) (NASDAQ: SHLT) (SIX: SHLTN), a provider and developer of advanced personal telemedicine solutions, on Monday announced the soft launch of the SmartHeart membership program in the US, marking a significant step forward in at-home healthcare.
This program is part of SHL's Direct-to-Consumer (D2C) initiative, offering a comprehensive subscription service that delivers at home professional cardiac care directly to the consumer.
The SmartHeart membership program is designed to revolutionise home-based access to cardiac care. It includes the innovative, user-friendly SmartHeart portable 12-lead ECG device, offering round-the-clock interpretation by board-certified cardiologists and on-demand telehealth visits. This initiative not only simplifies the process of conducting a full 12-lead ECG at home but also ensures convenient and dependable heart health management, meeting the evolving needs of today's healthcare consumers.
Subscribing members to SmartHeart are offered: a portable 12-lead ECG device,the SmartHeart ECG that allows high-quality 12-lead ECG performance anytime, anywhere; 24/7 cardiologist interpretation whereby subscribers receive expert ECG analysis from board-certified cardiologists; on-demand telehealth visits with onvenient access to medical professionals for timely consultations; and flexible subscription plans with tailored private-pay options ensure affordable access to advanced cardiac care.
SHL Telemedicine focuses on developing and marketing personal telemedicine systems, offering medical call centre services with a cardiovascular focus. The company provides services and devices to subscribers using telephonic and internet communication technology.
Medtronic announces new, long-term data from SPYRAL HTN-ON MED clinical trial
Senzime unveils next-gen TetraGraph TOF monitor at ANESTHESIOLOGY 2024; US shipments to begin in Q4
Abbott launches new clinical trial to improve results in patients with advanced heart failure
United Therapeutics reaches milestone with 500th lung transplant via ex vivo lung perfusion service
Adocia patents stable hormone combinations for obesity and diabetes
GE HealthCare expands AI-enabled enterprise imaging with Blackford integration
Viatris reports positive results for EFFEXOR in GAD treatment in Japan
ALK secures U.S. FDA approval for AccuTest Allergy Skin Testing Devices
Brain+ launches Ayla CST Assistant following UK regulatory approval
Accelerate Diagnostics receives FDA clearance for automated blood culture system
Photocure's partner Asieris presents Cevira Phase III subgroup analysis at 2024 CSCO Annual Meeting
Boston Scientific's FARAPULSE Pulsed Field Ablation system receives Japanese regulatory approval